Keyword : immunotherapy
Functional status of the thyroid gland as a factor modifying the level of PD-L1 expression by tumor cells and immunocompetent T cells of the paratumoral microenvironmentAuthors: Kolomiiets А.А. Lyalkin S.A. Дата: 2026-06-04
Paradigm reset: modern approaches to lung cancer diagnosis and treatmentAuthor:Zviahina O.V. Т. 15, №3 (59)
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialТ. 14, №4 (56)
KEYNOTE-006 study: results of 10-year follow-up of pembrolizumab versus ipilimumab in advanced melanomaТ. 14, №4 (56)
From theory to practice. The art of lung cancer treatment
Management of immunotherapy toxicity: European Society for Medical Oncology (ESMO) clinical guidelines for diagnosis, treatment and patient follow-up
New therapeutic options in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemiaТ. 14, №1 (53)
Immunological markers of dendritic cell vaccine response in glioblastoma patientsAuthors: Skachkova O.V. Glavatskyi O.Ya. Zemskova O.V. Gorbach O.I.... Т. 14, №1 (53)
Expanding the role of immuno-oncology treatment in the management of patients with melanoma or triple-negative breast cancerТ. 13, №4 (52)
Modern approaches to the diagnosis and treatment of lymphoproliferative diseases
Prospects for the use of pembrolizumab in the treatment of previously untreated patients with advanced malignant pleural mesotheliomaAuthor:Nemish I.L. Т. 13, № 3 (51)
The value of the immunotherapy of alfa/beta defensins in the development of epitheliitis in patients with oropharyngeal cancerAuthors: Hirna H.A. Kostyshyn I.D. Rozhko M.M. Lukach Ye.V.... Т. 11, № 3-4 (43-44)
World Conference on Lung Cancer 2020: new in the treatment of advanced/metastatic NSCLC
Т. 11, № 1-2 (41-42)
Т. 11, № 1-2 (41-42)
Five-year overall survival and progression-free survival of patients with advanced NSCLC receiving pembrolizumab
T. 10, № 3-4 (39-40)
T. 10, № 3-4 (39-40)
